Both in Pharmaceuticals
Standard BioTools vs Immuneering
Over the past year LAB returned −48.2% and IMRX returned −41.1%; their daily moves had a correlation of -0.09.
LAB −48.2% IMRX −41.1%Growth of $1, one year, split-adjusted
| Metric | LAB | IMRX |
|---|---|---|
| Price | $0.6160 | $3.76 |
| Market cap | $243.1M | $243.5M |
| Today | +0.85% | +2.17% |
| 1 month | −14.7% | −1.8% |
| 6 months | −36.4% | −27.6% |
| Year to date | −51.9% | −42.9% |
| 1 year | −50.3% | −42.7% |
| Revenue growth (YoY) | −0.9% | — |
| Gross margin | 55.9% | — |
| Net margin | 69.6% | — |
| P/E (TTM) | 1.8× | — |
| Price / sales | 2.9× | — |
| Net cash | $460.8M | $145.4M |
| Dividend yield | — | — |
| Volatility (60d) | 45.6% | 52.5% |
| Short % of float | 1.1% | 29.2% |
| Next earnings | — | — |
Shading marks the stronger figure where one clearly exists (lower is better for valuation and volatility).